A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination with Glofitamab in Participants with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506699-29-00

Acronym

BP43131

Enrollment

Registered

2024-01-29

Start date

2022-03-03

Completion date

2024-08-01

Last updated

2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma (r/r NHL)

None listed

Sex/Gender

All

Age

18 Years to No maximum

Denmark, France, Italy

None listed

Source: EU CTIS · Data processed: Feb 4, 2026